Navigation Links
The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority
Date:4/1/2011

WHITE PLAINS, N.Y., April 1, 2011 /PRNewswire/ -- Once again, the Annual Report to the Nation on the Status of Cancer shows a continued decline in diagnoses and deaths for many types of cancers. This encouraging news can be attributed primarily to preventive measures such as cessation of smoking and improved diet, and early detection.

(Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO)

But for many cancers, such as the blood cancers, early detection is rare, there are no measures that can be taken to prevent the onset of the disease, and they are still killing too many. In these cases, the only solution is continued research to find better treatments and cures once the diagnosis is made.

It is for this reason that many voluntary disease organizations have created programs to accelerate therapies from laboratories to patients. We recognize that funding research is costly and difficult, particularly in these trying economic times, particularly for orphan diseases such as blood cancers where producing these treatments may not always be cost-effective for drug companies.

We have to be more proactive and innovative in our approaches to funding drug development, not only funding laboratory research, but also partnering with biotechnology companies on high-prospect research projects, or by providing much needed expertise to help academics bring their discoveries to market.  We are continually searching for new ways to ensure that scientific discoveries are not stuck collecting dust on academic shelves, but are given the boost they need to cross the chasm that swallows so many promising findings.

The Federal government also recognizes this need to get more treatments to patients faster.  A key provision of the federal Affordable Care Act that has received little attention is the creation by Congress of the Cures Acceleration Network (CAN). This program, which would be administered by Frances Collins, Ph.D.,
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
2. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
3. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
4. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
5. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
6. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
7. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. The Leukemia & Lymphoma Society and The International Waldenstroms Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research
10. Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
11. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 VetStem Biopharma, ... Animal Health, Jeffrey Schaffer, DVM, as Director of ... 15 years of experience in the veterinary regenerative ... addition to our veterinarian lead organization”. Dr. ... “Dr. Schaffer will be responsible for all technical ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... the addition of the "Separation Systems ... offering. Macromolecules which include protein, ... or are broken into smaller molecules, during ... separation requires various advanced systems like centrifugation, ...
(Date:5/5/2015)... 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... trading on OTCQB  Marketplace, the market for developmental ... for a continuous public market for trading shares ... quotes and market information on us through ... includes U.S. and international companies in venture stage, ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and other chronic ... create an independent analysis designed to reflect the ... over time. This model will be used to ... for CHF, could have on those groups of ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... a company developing next generation biologics for the treatment and ... OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with ... Stage IV melanoma had initiated. The study has commenced recruiting ... Germany and Australia due to open later in the year. ...
... Zenobia Therapeutics, Inc., the leader in fragment-based lead ... announced successful completion of the first phase of ... subsidiary of Biogen Idec (Nasdaq: BIIB ... access to Zenobia,s technology and expertise in structural ...
... OAKWOOD VILLAGE, Ohio, April 14 ViewRay Incorporated, a ... tranche of their $25M Series B financing. Funding was ... towards the development of their image guided cancer therapy ... OrbiMed Advisors and Fidelity Biosciences, and was joined by ...
Cached Biology Technology:BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2ViewRay Incorporated Closes $15M Tranche of Series B Financing and Announces Partnership with Siemens AG 2
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... up to an undergraduate class, being given a dissertation ... improve on it. This was the experience ... London,s) Department of Science and Technology Studies between 2000 ... teaching is a full-blown academic monograph published this month ...
... microscopy to a major marine biology challenge, researchers ... and attack patterns of two tiny but deadly ... Bay and other waterways. The study, reported ... Proceedings of the National Academy of Sciences, focused ...
... standards for phosphorus releases into the Everglades seem sufficient ... from damage, but pollutant levels still reach double or ... edges. A six-year study led by Duke University ... in two research sites inside the Everglades. In ...
Cached Biology News:Researchers view swimming tactics of tiny aquatic predators 2Researchers view swimming tactics of tiny aquatic predators 3Everglades phosphorus limits on the right track, but more is needed 2Everglades phosphorus limits on the right track, but more is needed 3
... Reduce bench time to just 15 minutes! ... paralles that can be drawn between this exciting ... of instant foods. Instant meals consumed by ... format and are reconstituted by adding water. ...
...
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
Biology Products: